Boehringer Ingelheim Press Release

03/19/2018 - 07:31 FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
03/13/2018 - 07:05 Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
02/21/2018 - 00:54 Boehringer Ingelheim: 2018 European PRRS Research Award open for submissions until
02/16/2018 - 05:02 Systemic Sclerosis World Congress: Inspirational patient stories reveal the challenging realities of living with devastating rare disease
02/09/2018 - 05:26 Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimers trials
01/15/2018 - 02:20 The World Association for Buiatrics and Boehringer Ingelheim announce the 2018 'Ruminant Well-Being Awards
01/08/2018 - 23:31 BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
01/03/2018 - 04:01 Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M
12/19/2017 - 02:55 Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
12/18/2017 - 04:34 Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
12/15/2017 - 04:26 Change in the Board of Managing Directors at Boehringer Ingelheim
12/11/2017 - 08:48 Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
11/20/2017 - 04:59 Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via to unlock their full potential
11/08/2017 - 03:12 Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
11/02/2017 - 06:45 Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
10/30/2017 - 04:00 Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
09/29/2017 - 10:46 Boehringer Ingelheim and FEI partner to promote equine health and education
09/28/2017 - 08:07 Boehringer Ingelheim joins forces with partners around the world towards the elimination of rabies
09/07/2017 - 10:28 Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
09/07/2017 - 07:47 Boehringer Ingelheim is initiating Phase IIa study for the development of a new treatment for diabetic retinopathy a leading cause of vision-loss
08/24/2017 - 05:27 Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
08/03/2017 - 05:07 Next generation of veterinary scientists gathers at National Institutes of Health for National Veterinary Scholars Symposium
08/02/2017 - 02:12 Boehringer Ingelheim achieves good growth in the first half of 2017
07/23/2017 - 22:35 People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey
06/29/2017 - 01:23 'More than Systemic Sclerosis: The Inside Story' - patients reveal the unseen impact of lung fibrosis
06/08/2017 - 06:41 Boehringer Ingelheim builds Digital Lab BI X with focus on innovative digital solutions in healthcare
05/16/2017 - 05:29 Boehringer Ingelheim strengthens early science portfolio through comprehensive multifaceted partnership with Peking University
05/15/2017 - 22:18 Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China
05/10/2017 - 02:50 Boehringer Ingelheim Phase II trial now enrolling patients with the kidney disease Lupus Nephritis
04/05/2017 - 03:33 Boehringer Ingelheim: A New World Leader in Animal Health
04/05/2017 - 02:19 Successful financial year 2016 for Boehringer Ingelheim
03/30/2017 - 06:33 Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries
03/02/2017 - 04:02 Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
03/02/2017 - 01:05 Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million
02/28/2017 - 00:47 New global survey results show: 2 out of 3 patients said they were involved in the decision-making process about the most appropriate treatment in IPF
02/15/2017 - 08:22 Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
02/09/2017 - 04:52 Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung
01/01/2017 - 20:45 Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
11/28/2016 - 07:10 Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
11/14/2016 - 04:46 New analysis from the IntroDia survey reveals how people with type 2 diabetes are informed of their diagnosis
11/08/2016 - 02:23 New European study highlights differing priorities in physicians therapy goals when treating advanced lung cancer patients
10/26/2016 - 07:32 Most successful animal health vaccine of all time reaches milestone of two billion pigs being protected
10/21/2016 - 01:04 Three projects win 2016 European PRRS Research Award sponsored by Boehringer Ingelheim Animal Health
10/13/2016 - 00:13 Boehringer Ingelheim announces agreement with Ceva Sante Animale for the sale of certain Merial assets
10/08/2016 - 22:36 Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016
10/08/2016 - 22:31 Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
09/29/2016 - 07:09 Boehringer Ingelheim and SARAH CANNON Research Institute launch strategic collaboration to develop novel immune-oncology therapies
09/26/2016 - 02:03 Preventing disease: One billion pigs vaccinated with Ingelvac PRRS MLV
09/01/2016 - 06:33 Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE immuno-oncology drug for multiple myeloma
08/28/2016 - 22:56 Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia
08/03/2016 - 08:29 Boehringer Ingelheim: Growth in all core businesses
07/21/2016 - 06:46 CZ Veterinaria and Boehringer Ingelheim Animal Health announce cooperation to bring innovative sow vaccine Entericolix to the European market
07/20/2016 - 07:54 The European Stroke Organisation and Boehringer Ingelheim launch the Angels Initiative, a unique healthcare initiative to improve acute stroke care across Europe
07/14/2016 - 06:49 Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
07/13/2016 - 09:38 Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07/07/2016 - 08:42 Marina von Keyserlingk and Daniel Weary win first Ruminant Well-being Award
07/04/2016 - 09:07 Gaia Novarino wins Boehringer Ingelheims FENS Award 2016 for Exceptional Research in Neuroscience
06/27/2016 - 02:59 Sanofi and Boehringer Ingelheim have reached definitive agreements to swap Sanofis Animal Health and Boehringer Ingelheims Consumer Healthcare businesses
06/10/2016 - 01:26 Simone Menne new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance
06/07/2016 - 08:55 Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
05/31/2016 - 08:59 Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
05/25/2016 - 08:37 Boehringer Ingelheim increases access to the medication for the treatment of HIV/Aids
05/24/2016 - 00:47 IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohns disease
05/23/2016 - 09:04 Pooled data analysis of placebo-controlled trials confirms improvement in quality of life within 4 weeks of using oral bisacodyl/sodium picosulfate
05/23/2016 - 08:56 Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
05/11/2016 - 07:16 Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
05/10/2016 - 08:45 New claim for use of Metacam 20mg/ml in sheep simultaneously granted in Australia, Canada and New Zealand
04/19/2016 - 06:45 Boehringer Ingelheim has a successful 2015 financial year
04/19/2016 - 01:23 Boehringer Ingelheim presented the 2015 results and an outlook for 2016 at the Annual Press Conference on 19 April 2016 in Ingelheim.
04/18/2016 - 06:43 New concept and design of Corporate website as central web hub with customer-focused news and stories
04/08/2016 - 04:38 The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
04/07/2016 - 07:34 Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
04/04/2016 - 06:00 Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) in Emergency Situations
03/30/2016 - 05:18 Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine
03/23/2016 - 12:39 Boehringer Ingelheim launches RE-COVERY DVT/PE: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa (dabigatran etexilate)
03/15/2016 - 07:04 2016 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until
03/08/2016 - 08:58 New Analyses: Adding SPIRIVA Respimat Effective for Uncontrolled Asthma Regardless of Allergy Subtype 1,2,3
03/07/2016 - 08:38 AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
03/01/2016 - 04:41 Boehringer Ingelheim Animal Health supports independent PCV2 research with total of 650,000
02/29/2016 - 09:12 European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung
02/29/2016 - 05:08 New survey gives voice to people living with a rare and devastating lung disease: When I think of IPF I think of breathlessness
02/25/2016 - 05:10 New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
02/10/2016 - 11:57 The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
02/04/2016 - 11:20 SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
01/15/2016 - 11:04 World Association for Buiatrics and Boehringer Ingelheim Animal Health announce “Ruminant Well-being Award”
01/13/2016 - 15:21 Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
12/22/2015 - 07:07 Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
12/21/2015 - 07:29 Boehringer Ingelheim 3 rd -generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
12/18/2015 - 09:12 Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
12/15/2015 - 11:58 Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
12/14/2015 - 11:01 Initiation of first multinational study to evaluate safety of OFEV ® (nintedanib) with add-on of pirfenidone in patients with IPF
12/07/2015 - 23:55 New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
12/02/2015 - 02:36 Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
11/29/2015 - 23:49 Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
11/26/2015 - 10:08 Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
11/16/2015 - 12:38 Boehringer Ingelheim named one of the most innovative companies worldwide
11/13/2015 - 12:59 New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
11/11/2015 - 12:30 Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs
Copy and paste this code to display this page on your website .
Syndicate content